biostudies-literatureUnknown22(1)Pageaux GP<h4>Background</h4>In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the French ANRS CO22 HEPATHER cohort.<h4>Methods</h4>We identified HCV patients who had experienced an episode of decompensated cirrhosis. Study outcomes were all-cause mortality, liver-related or non-liver-related deaths, hepatocellular carcinoma, liver transplantation. Secondary study outcomes were sustained virological response and its clinical benefits.<h4>Results</h4>559 patients met the identification criteria, of which 483 received direct antiviral agents and 76 remained untreated afteBMC infectious diseases94https://www.ebi.ac.uk/biostudies/studies/S-EPMC8796427biostudies-literatureClinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.PMC8796427Dharancy SLuckina EBensenane MBoursier JBabouri AKeser SGoria OMessaoudi NBrener ASaillard EDorival CAsselah TAhmed SNSGiuily NOuedraogo CRenard IAngoulevant BLafrance MJCagnot CPetrov-Sanchez VRazi EFontaine HPauleau CMouillot TBacq YMuti LBismuth MBrigitte CDebette-Gratien MMerbah Sde Ledinghen VTruchi RStahl OZoulim FBonardi KLeroy VScoazec GBernard MAHabersetzer FFoucher JHiriart JBRipault MPBonny CPageaux GPCarrier PAndreani TLunel FPeron JMPannetier GGiboz DLassailly GDunette JDe Dieuleveult BGelu-Simeon MBonnet DCostes LVarault ANahon POules VArtu FGoin HBaumert TFWadouachi LAyour LBardou MChau FPayssan-Sicart VTran ADecaens TPotier PAnty RAntonini TArchambeaud IAnsaldi CMaynard MLoustaud-Ratti VGrard VMontialoux HBronowicki JPGelsi EBourliere MMoussali JBrule SVallee JDHadi WTeloule FGanne NHartig-Lavie KSamuel DFaure SChevalier CCoilly ACavellec MBarbereau DHabes SFrench ANRS CO22 Hepather CohortHubert IMonard RLouvet AFrancois MChevance ARiachi GDiallo AChazouilleres OMetivier SBoutoille DLaunay SPinot FFroissart BJezequel CTarallo Ld'Alteroche LLabarriere DBotta-Fridlund DBarrault CBailly FHagege HLatournerie MMutter CBureau CRaffi FThabut DZarski JPGilibert AFaure MPol SGoderel IFilipe VSerfaty LBenhida JVallet-Pichard ALamblin GHassani-Nani SGoepfert PBarraud HNani AAbergel AChibah AGournay JGrando-Lemaire VHilleret MNBeaudoin MNzinga CLBoyer NDoffoel MCanva VNicolas CGeist CMinello ACales PChermak FLaligant ALegendre ARabot ASimo-Noumbissie PAmmour DRosa ILannes ACaillo LMathurin PCastelnau CCarrat FRobic MAGuyader DPomes CAlric LBillaud EIrles-Depe MSogni PCausse XAmara NBTateo MJacques JPortal IfalseClinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.<h4>Background</h4>In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the French ANRS CO22 HEPATHER cohort.<h4>Methods</h4>We identified HCV patients who had experienced an episode of decompensated cirrhosis. Study outcomes were all-cause mortality, liver-related or non-liver-related deaths, hepatocellular carcinoma, liver transplantation. Secondary study outcomes were sustained virological response and its clinical benefits.<h4>Results</h4>559 patients met the identification criteria, of which 483 received direct antiviral agents and 76 remained untreated afte2022-01-01T00:00:00Z2022 Jan2026-05-31T01:03:52.281Z2025-04-04T11:31:36.507ZS-EPMC87964273508648110.1186/s12879-022-07076-0